Drugs / NY-ESO-1 lp
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00112242 | Feb 2004 → Mar 2013 | melanoma | Centre Hospitalier Universitaire Vaudois | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NY-ESO-1 lp | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00112242 ↗ |
| Route | Subcutaneous | “In this phase I trial, 19 patients received a mean of 8 (range 1-12) monthly vaccines s.c. composed of the long synthetic NY-ESO-179-108 peptide and CpG-B (PF-3512676),...” PMID 27853637 ↗ Sep 2016 |